📊 NVNO Key Takeaways
Is enVVeno Medical Corp (NVNO) a Good Investment?
enVVeno shows exceptional revenue growth (+747% YoY) with positive gross margins indicating product-market validation, but operates in an unsustainable cash burn environment with less than one year of runway at current burn rates (-$3.2M operating cash flow against $2.6M cash). The company remains far from profitability with -$3.8M net loss despite improving YoY, necessitating near-term capital raise or dramatic revenue acceleration to survive.
enVVeno remains pre-commercial with minimal revenue and extremely negative margins and free cash flow, indicating an unsustainable operating profile on fundamentals. Despite a debt-free balance sheet and low liabilities, cash appears limited relative to the ~$15.6M annual operating burn, implying reliance on near-term external financing. Until revenue scales materially and gross margins improve, risk to continuity and dilution remains high.
enVVeno Medical Corp Key Strengths (NVNO)
- Exceptional revenue growth of 747.4% YoY demonstrates strong commercial traction
- Positive gross margin (19.4%) indicates viable unit economics and product value
- Pristine balance sheet with zero long-term debt and minimal liabilities ($2.4M)
- Improving loss metrics year-over-year (net loss improved 10.8%, EPS improved 25.8%)
- Exceptional liquidity position (11.89x current ratio) relative to liabilities
- Debt-free balance sheet with low liabilities
- Very high current ratio indicating near-term liquidity
- YoY improvement in losses and strong revenue growth off a small base
NVNO Stock Risks: enVVeno Medical Corp Investment Risks
- Critical cash runway: Operating burn of $3.2M against cash reserves of only $2.6M suggests less than one year of operations
- Revenue base remains microscopic at $161K, insufficient to support operating expense structure
- Extreme operating losses (-$4.1M) and negative ROE/ROA indicate fundamental business model imbalance
- Company dependent on capital raise or dramatic revenue acceleration for survival
- Early-stage commercialization risk with limited commercial history
- Severe negative operating cash flow and large operating losses
- Limited cash relative to burn, raising dilution/financing risk
- Early-stage commercialization with low gross margin and execution risk
Key Metrics to Watch
- Monthly recurring revenue growth and customer acquisition rate
- Operating burn rate trajectory and path to cash flow breakeven
- Cash position and timeline until next capital raise requirement
- Gross margin sustainability as revenue scales
- Timeline to product-market fit validation and commercial inflection
- Operating cash flow (burn rate)
- Cash & equivalents (runway)
enVVeno Medical Corp (NVNO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.89x current ratio provides a solid financial cushion.
NVNO Profit Margin, ROE & Profitability Analysis
NVNO vs Healthcare Sector: How enVVeno Medical Corp Compares
How enVVeno Medical Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is enVVeno Medical Corp Stock Overvalued? NVNO Valuation Analysis 2026
Based on fundamental analysis, enVVeno Medical Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
enVVeno Medical Corp Balance Sheet: NVNO Debt, Cash & Liquidity
NVNO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: enVVeno Medical Corp's revenue has declined by 93% over the 5-year period, indicating business contraction. The most recent EPS of $-44.53 indicates the company is currently unprofitable.
NVNO Revenue Growth, EPS Growth & YoY Performance
NVNO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $31.2K | -$1.2M | N/A |
| Q2 2020 | $31.2K | -$1.2M | N/A |
| Q1 2020 | $31.2K | -$1.2M | N/A |
| Q3 2019 | $31.2K | -$1.5M | N/A |
| Q2 2019 | $31.2K | -$1.6M | N/A |
| Q1 2019 | $31.1K | -$1.6M | N/A |
| Q3 2018 | $27.9K | -$1.5M | N/A |
| Q2 2018 | $38.8K | -$1.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
enVVeno Medical Corp Dividends, Buybacks & Capital Allocation
NVNO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for enVVeno Medical Corp (CIK: 0001661053)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NVNO
What is the AI rating for NVNO?
enVVeno Medical Corp (NVNO) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NVNO's key strengths?
Claude: Exceptional revenue growth of 747.4% YoY demonstrates strong commercial traction. Positive gross margin (19.4%) indicates viable unit economics and product value. ChatGPT: Debt-free balance sheet with low liabilities. Very high current ratio indicating near-term liquidity.
What are the risks of investing in NVNO?
Claude: Critical cash runway: Operating burn of $3.2M against cash reserves of only $2.6M suggests less than one year of operations. Revenue base remains microscopic at $161K, insufficient to support operating expense structure. ChatGPT: Severe negative operating cash flow and large operating losses. Limited cash relative to burn, raising dilution/financing risk.
What is NVNO's revenue and growth?
enVVeno Medical Corp reported revenue of $161.0K.
Does NVNO pay dividends?
enVVeno Medical Corp does not currently pay dividends.
Where can I find NVNO SEC filings?
Official SEC filings for enVVeno Medical Corp (CIK: 0001661053) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NVNO's EPS?
enVVeno Medical Corp has a diluted EPS of $-5.89.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NVNO's fundamental grade?
Based on our AI fundamental analysis in June 2026, enVVeno Medical Corp has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NVNO stock overvalued or undervalued?
Valuation metrics for NVNO: ROE of -16.2% (sector avg: 15%), net margin of -2,390.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NVNO's AI grade for 2026?
Our dual AI analysis gives enVVeno Medical Corp a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NVNO's free cash flow?
enVVeno Medical Corp's operating cash flow is $-3.2M, with capital expenditures of $5.0K. FCF margin is -2,014.3%.
How does NVNO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,390.7% (avg: 12%), ROE -16.2% (avg: 15%), current ratio 11.89 (avg: 2).